Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: A case report

Miranda Verschraagen, Epie Boven, Ivon Zegers, Frederick H. Hausheer, Wim J F Van Der Vijgh

Research output: Contribution to journalArticlepeer-review


Purpose: BNP7787 (2′,2′-dithio-bis-ethane sulfonate sodium) is a novel protector against cisplatin-induced toxicities. The pharmacokinetics of BNP7787 and its metabolite mesna were investigated in plasma and ascites of a cancer patient. We also evaluated potential pharmacokinetic interactions between BNP7787 and cisplatin. Methods: BNP7787 and mesna were measured as mesna in deproteinized plasma and ascites using high-performance liquid chromatography with an electrochemical detector provided with a wall-jet gold electrode. Results: After the i.v. administration of 41 g/m2 BNP7787, BNP7787 and mesna had a half-life of 1.5 and 3.4 h, respectively. The auc of mesna was approximately 8% of the AUC of BNP7787. Coadministration of cisplatin did not appear to influence the plasma concentration-time curves of BNP7787 and mesna. In ascites, approximately 0.02% of the BNP7787 dose was present as mesna, whereas approximately 4% of the dose was present as BNP7787 at the time of the maximum concentration. Conclusions: It can be concluded that the presence of ascites did not have a major impact on the pharmaco-kinetics of BNP7787 and coadministration of cisplatin did not influence the pharmacokinetics of BNP7787 and mesna.

Original languageEnglish (US)
Pages (from-to)525-529
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Issue number6
StatePublished - Jun 1 2003
Externally publishedYes


  • Ascites
  • BNP7787
  • Mesna
  • Pharmacokinetics
  • Plasma

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology


Dive into the research topics of 'Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: A case report'. Together they form a unique fingerprint.

Cite this